Subtype
Endocrine Carcinoma
CI-CAN-00000838Explore in graph →
575 active trials16 approved drugs58 evidence items
- NCIt
- C215715
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000838Explore in graph →
Clinical trials
1,791 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (236)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07485920 | A Prospective, Multicenter Exploratory Clinical Study on Consolidation Therapy With Tislelizumab Combined With Nintedanib for Limited-stage Small Cell Lung Cancer | not yet recruiting | Phase 4 | 20 | The Affiliated Hospital of Qingdao UniversityOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT04211337 | A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer(LIBRETTO-531) | active not recruiting | Phase 3 | 291 | Loxo Oncology, Inc.INDUSTRY | 20 |
| Mar 19, 2026 |
| clinicaltrials |
| NCT05500391 | Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring(SUR-CAN) | recruiting | Phase 2 | 88 | Centre Oscar LambretOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT07480213 | Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)(DART-NK-SCLC) | recruiting | Phase 1 / Phase 2 | 60 | Beijing BiotechINDUSTRY | 1 | Mar 18, 2026 | clinicaltrials |
| NCT04119024 | Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors | recruiting | Phase 1 | 18 | Anusha KalbasiOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT04802174 | Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers | active not recruiting | Phase 1 / Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | Mar 17, 2026 | clinicaltrials |
| NCT05746208 | Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors | recruiting | Phase 2 | 29 | University of California, San FranciscoOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT07001995 | Limertinib Plus Carboplatin and Etoposide for EGFR-mutant NSCLC With SCLC Transformation After EGFR-TKI Progression | not yet recruiting | Phase 2 | 30 | Hunan Province Tumor HospitalOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT07472647 | SYS6090 Combination Therapy in Advanced Lung Cancer | not yet recruiting | Phase 1 / Phase 2 | 596 | Shanghai JMT-Bio Inc.INDUSTRY | 0 | Mar 16, 2026 | clinicaltrials |
| NCT04358107 | Optimal Methods of Disease Progression and Survival Analysis in Children and Adults Patients With Adrenocortical Cancer (ACC) | active not recruiting | — | 1,000 | National Cancer Institute (NCI)NIH | 1 | Mar 12, 2026 | clinicaltrials |
| NCT06157827 | A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma | recruiting | Phase 1 / Phase 2 | 178 | Nanjing Leads Biolabs Co.,LtdINDUSTRY | 1 | Mar 12, 2026 | clinicaltrials |
| NCT03071406 | Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma | active not recruiting | Phase 2 | 50 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT03753919 | Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial(DUTHY) | terminated | Phase 2 | 79 | Grupo Espanol de Tumores NeuroendocrinosOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT06681220 | Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLC(Relapsed SCLC) | recruiting | Phase 1 / Phase 2 | 166 | VA Office of Research and DevelopmentFED | 1 | Mar 11, 2026 | clinicaltrials |
| NCT02402920 | Pembrolizumab and Concurrent Chemoradiotherapy or Radiation Therapy in Treating Patients With Small Cell Lung Cancer | completed | Phase 1 | 83 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT06223659 | EMLA Topical Cream for Treatment of Pain in Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy for Skin Cancers | recruiting | Phase 2 | 100 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT00830557 | Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic Disorders | recruiting | — | 20,000 | Mayo ClinicOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT04332653 | NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 215 | NeoImmuneTechINDUSTRY | 1 | Mar 9, 2026 | clinicaltrials |
| NCT07391813 | SNB-101 for Treatment of Extensive Stage Small Cell Lung Cancer(SNB-101-101) | recruiting | Phase 1 / Phase 2 | 55 | SN BioScienceINDUSTRY | 1 | Mar 9, 2026 | clinicaltrials |
| NCT04170946 | Talazoparib and Thoracic RT for ES-SCLC(Talazoparib) | recruiting | Phase 1 | 24 | University Health Network, TorontoOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT07010263 | A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy(AK112-311) | recruiting | Phase 3 | 560 | AkesoINDUSTRY | 1 | Mar 5, 2026 | clinicaltrials |
| NCT03223155 | Concurrent or Sequential Immunotherapy and Radiation Therapy in Patients With Metastatic Lung Cancer(COSINR) | active not recruiting | Phase 1 | 78 | University of ChicagoOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT05068232 | Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES) | recruiting | Phase 2 | 49 | University of ChicagoOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT05546268 | Study of Oral MRT-2359 in Selected Cancer Patients | active not recruiting | Phase 1 / Phase 2 | 174 | Monte Rosa Therapeutics, IncINDUSTRY | 1 | Mar 3, 2026 | clinicaltrials |
| NCT06719700 | Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer | recruiting | Phase 2 | 47 | Sun Yat-sen UniversityOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT07219251 | Engagement of Veterans With Lung Cancer(EVLC) | recruiting | N/A | 194 | Palo Alto Veterans Institute for ResearchOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT04894591 | To Assess the Effectiveness and Safety of Zepzelca in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC)(SCLC) | completed | — | 272 | Jazz PharmaceuticalsINDUSTRY | 2 | Feb 27, 2026 | clinicaltrials |
| NCT07110103 | Golidocitinib With PD-1 Inhibitors as Maintenance Treatment for Previously Untreated ES-SCLC(JACKPOT38) | recruiting | Phase 2 | 20 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT05280470 | Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)(IDeate-Lung01) | active not recruiting | Phase 2 | 187 | Daiichi SankyoINDUSTRY | 8 | Feb 25, 2026 | clinicaltrials |
| NCT07434518 | A Real-World Study Evaluating the Efficacy and Safety of Adebrelimab in Patients With Advanced SCLC | recruiting | — | 500 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT04471727 | A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001) | active not recruiting | Phase 1 / Phase 2 | 232 | Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 1 | Feb 24, 2026 | clinicaltrials |
| NCT07425795 | Tislelizumab Combined With Chemotherapy Followed by Thoracic Consolidation Radiotherapy in the First-line Treatment of Extensive Stage Small Cell Lung Cancer | recruiting | Phase 2 | 36 | Chongqing University Cancer HospitalOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT06305962 | 177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors | recruiting | Early Phase 1 | 30 | Radiopharm Theranostics, LtdINDUSTRY | 1 | Feb 19, 2026 | clinicaltrials |
| NCT05496036 | Neoadjuvant PD-1 Blockade in Resectable Merkel Cell Carcinoma(MCC) | recruiting | Phase 2 | 15 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT06006013 | Cabozantinib in Combination With Pembrolizumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Adrenal Cortical Cancer | recruiting | Phase 2 | 21 | Emory UniversityOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT07030257 | Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 150 | Tasca TherapeuticsINDUSTRY | 1 | Feb 18, 2026 | clinicaltrials |
| NCT06151236 | Neoadjuvant Nivolumab and Relatlimab in Merkel Cell Carcinoma | recruiting | Phase 2 | 20 | Melanoma Institute AustraliaOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT07413042 | A Phase I Study to Evaluate the Safety and Preliminary Efficacy of [225Ac]Ac-DOTATATE Injection Combined With Tislelizumab in the Maintenance Treatment Period for Patients of Extensive-stage Small Cell Lung Cancer (ES-SCLC) With Somatostatin Receptors (SSTR)+ as First-line Treatment | recruiting | Phase 1 | 24 | Peking University Cancer Hospital & InstituteOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT07414927 | A Clinical Study for the Efficacy and Safety of BL0020 Injection in Patients With Small Cell Lung Cancer Transformed From Non-Small Cell Lung Cancer Following EGFR TKI Therapy | not yet recruiting | Phase 1 / Phase 2 | 48 | Shanghai Best-Link Bioscience, LLCINDUSTRY | 1 | Feb 17, 2026 | clinicaltrials |
| NCT07288073 | TIL Therapy in cSCC and MCC | recruiting | Phase 2 | 14 | Karam Khaddour, MD, MSOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT03830918 | Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy | active not recruiting | Phase 1 / Phase 2 | 59 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT06730685 | Sarcopenia and Cachexia in Patients With Lung Cancer(PHILUCA) | enrolling by invitation | — | 160 | Zealand University HospitalOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT07050472 | Durvalumab After Concurrent Chemoradiotherapy (cCRT) for Limited-stage Small-cell Lung Cancer (LS-SCLC) | completed | — | 45 | Anhui Shi, MDOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT02143726 | Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer | active not recruiting | Phase 2 | 35 | Alliance for Clinical Trials in OncologyOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT06937905 | Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs)(TARLANEC) | recruiting | Phase 3 | 129 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT06943235 | Study of Probiotics Combined With Concurrent Hyperfractionated ChemoRadiotherapy and Adebrelimab Immunomaintenance in the Treatment of Limited-stage Small Cell Lung Cancer (LS-SCLC) | recruiting | Phase 2 | 60 | Fudan UniversityOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT07398560 | Adebrelimab Combined With Oral Etoposide for Elderly Patients and Patients With Poor Performance Status in Small Cell Lung Cancer: An Exploratory Clinical Study | not yet recruiting | Phase 2 | 47 | The Third Affiliated Hospital of Harbin Medical UniversityOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT07400575 | Anlotinib in Cross-line Treatment of NSCLC and SCLC(NSCLC SCLC) | not yet recruiting | — | 350 | Henan Cancer HospitalOTHER_GOV | 0 | Feb 10, 2026 | clinicaltrials |
| NCT05551117 | A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors(Tamarack) | terminated | Phase 2 | 192 | MacroGenicsINDUSTRY | 9 | Feb 9, 2026 | clinicaltrials |
| NCT07390565 | YSQTG Combined With Immuno-chemotherapy for Extensive-Stage Small Cell Lung Cancer | enrolling by invitation | N/A | 308 | LI FENGOTHER | 1 | Feb 9, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Mar 20, 2026source: clinicaltrials